Your browser doesn't support javascript.
loading
Expression of TFH Markers and Detection of RHOA p.G17V and IDH2 p.R172K/S Mutations in Cutaneous Localizations of Angioimmunoblastic T-Cell Lymphomas.
Leclaire Alirkilicarslan, Ariane; Dupuy, Aurélie; Pujals, Anaïs; Parrens, Marie; Vergier, Béatrice; Robson, Alistair; Delfau-Larue, Marie-Hélène; Ingen-Housz-Oro, Saskia; Chosidow, Olivier; Haioun, Corinne; Beylot-Barry, Marie; Merlio, Jean-Philippe; Copie-Bergman, Christiane; Gaulard, Philippe; Ortonne, Nicolas.
Affiliation
  • Leclaire Alirkilicarslan A; *Pathology Department, Henri Mondor Hospital, Assistance Publique-Hôpitaux de Paris †INSERM U955 équipe 9, Institut Mondor de Recherche Biomédicale ‡Paris Est Creteil University (UPEC) ¶Biological Immunology Department, Henri Mondor Hospital, Assistance Publique-Hôpitaux de Paris #Dermatology department, Henri Mondor Hospital, Assistance Publique-Hôpitaux de Paris **Hematology Department, Lymphoid hemopathy Unit, Henri Mondor Hospital, Assistance Publique-Hôpitaux de Paris, Créteil ††Dermatology
Am J Surg Pathol ; 41(12): 1581-1592, 2017 Dec.
Article in En | MEDLINE | ID: mdl-28945625
ABSTRACT
Skin biopsies of 41 angioimmunoblastic T-cell lymphoma patients were retrospectively analyzed for the expression of follicular helper T-cell (TFH) markers, Epstein-Barr virus (EBV), and the presence of RHOA (p.G17V) and IDH2 (p.R172K/S) mutations using allele-specific polymerase chain reaction. We categorized cases into 4 distinctive patterns (1) low-density lymphocytic perivascular infiltrates (n=11), (2) dense perivascular infiltrates with atypical cells and occasional inflammatory cells (n=13), (3) diffuse infiltrates reminiscent of angioimmunoblastic T-cell lymphoma (n=4), or (4) other aspects (n=13). Two EBV and 2 plasmacytoid lymphoproliferative disorders were seen. We observed variable expression of TFH markers (CD10 [50%], BCLB6 [84%], PD1 [94%], CXCL13 [84%], and ICOS [97.5%]), and EBV B-blasts (26%). A TFH phenotype was identified in 82% and 73%, respectively, of cases with the most challenging patterns 1 and 2. TFH markers and EBV can thus help for diagnosis and are detected in samples with low-density infiltrates. We found RHOA G17V and IDH2 R172K/S mutations in the skin in 14/18 (78%) and 3/16 (19%) cases, respectively. The RHOA G17V mutation was identified in a proportion of biopsies with patterns 1 and 2, which represent a diagnostic challenge. The RHOA G17V mutation was detected both in the skin and lymph node (LN) biopsies in 7/9 (64%) cases, and in only the skin or the LN of 1 sample each. The frequency of RHOA G17V mutation was similar to that reported in LNs. It may represent a sensitive diagnostic marker in the skin, helpful in cases with low-density infiltrates.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Skin Neoplasms / Biomarkers, Tumor / Lymphoma, T-Cell, Cutaneous / T-Lymphocytes, Helper-Inducer / RhoA GTP-Binding Protein / Immunoblastic Lymphadenopathy / Isocitrate Dehydrogenase / Mutation Type of study: Diagnostic_studies / Prognostic_studies Limits: Humans Language: En Journal: Am J Surg Pathol Year: 2017 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Skin Neoplasms / Biomarkers, Tumor / Lymphoma, T-Cell, Cutaneous / T-Lymphocytes, Helper-Inducer / RhoA GTP-Binding Protein / Immunoblastic Lymphadenopathy / Isocitrate Dehydrogenase / Mutation Type of study: Diagnostic_studies / Prognostic_studies Limits: Humans Language: En Journal: Am J Surg Pathol Year: 2017 Document type: Article